Characteristics of the patients who underwent autologous stem cell transplantation in Myanmar from 2014 to 2016
| Age | 53-62 years |
| Sex | 4 males and 2 females |
| Myeloma stage | Durie-Salmon stage IIIA in 5 patients, 1 IIIA; International Staging System stage II-III |
| Induction | Bortezomib-thalidomide-dexamethasone induction |
| Remission status prior transplant | Stringent complete remission (CR) to very good partial remission (VGPR) |
| Time from diagnosis to transplant | 6 months to 5 years |
| Mobilization | Granulocyte colony-stimulating factor 10 μg/kg per day subcutaneously, except 1 case of 15 μg/kg per day; high-dose etoposide in 1 case |
| Peripheral blood stem cell harvest | Day 5-7 |
| Storage | In pharmaceutical refrigerator, at 2-4˚C, for 24-72 hours |
| Conditioning | High-dose melphalan (dose, 110-200 mg/m2) |
| Stem cell reinfusion | Reinfuse after high-dose melphalan without cryopreservation after 24-72 hours |
| Stem cell dose | 1.45 × 106-4.75 × 106/kg |
| Engraftment | Neutrophil engraftment: day 10-11; platelet engraftment: day 14-18 |
| Age | 53-62 years |
| Sex | 4 males and 2 females |
| Myeloma stage | Durie-Salmon stage IIIA in 5 patients, 1 IIIA; International Staging System stage II-III |
| Induction | Bortezomib-thalidomide-dexamethasone induction |
| Remission status prior transplant | Stringent complete remission (CR) to very good partial remission (VGPR) |
| Time from diagnosis to transplant | 6 months to 5 years |
| Mobilization | Granulocyte colony-stimulating factor 10 μg/kg per day subcutaneously, except 1 case of 15 μg/kg per day; high-dose etoposide in 1 case |
| Peripheral blood stem cell harvest | Day 5-7 |
| Storage | In pharmaceutical refrigerator, at 2-4˚C, for 24-72 hours |
| Conditioning | High-dose melphalan (dose, 110-200 mg/m2) |
| Stem cell reinfusion | Reinfuse after high-dose melphalan without cryopreservation after 24-72 hours |
| Stem cell dose | 1.45 × 106-4.75 × 106/kg |
| Engraftment | Neutrophil engraftment: day 10-11; platelet engraftment: day 14-18 |